Compare Amphastar Pharmaceuticals Inc (AMPH) vs Workday Inc (WDAY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Workday (WDAY) trades at $138.95, up 0.44% with a bullish technical signal. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $2.66 versus $2.51, continuing a trend of earnings outperformance. Revenue growth remains robust, projected to reach $9.9B in 2026, while the company maintains high gross margins of 75.77%. Recent news highlights AI-driven product growth with agentic AI ACV tripling year-over-year.

The outlook remains positive with a $157.30 analyst consensus price target representing 13% upside. Key opportunities include AI adoption driving larger expansion deals, while risks involve a pending California lawsuit over AI bias allegations and elevated valuation multiples. Operating cash flow strength at $2.46B supports continued investment in growth initiatives.